RecruitingCarcinoma, Non-small-Cell Lung
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
Eligible age
18+ yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.
Sponsor: Johnson & Johnson Enterprise Innovation Inc.
You may qualify if…
- ✓ Individuals with histologically or cytologically confirmed stage IIIB-IV non-small cell lung cancer (NSCLC)
- ✓ Part 1: NSCLC with a known actionable genetic mutation (for example, epidermal growth factor receptor \[EGFR\], anaplastic lymphoma kinase \[ALK\], c-ros oncogene 1 \[ROS1\], v-raf murine sarcoma viral oncogene homolog B1 \[BRAF\]) must have received all approved targeted therapies and have progressed
- ✓ Part 2: No targetable mutations (for example, EGFR \[epidermal growth factor receptor\], ALK \[anaplastic lymphoma kinase\], ROS1\[c-ros oncogene 1\], and BRAF \[B-Raf proto-oncogene, serine/threonine kinase\])
- ✓ Part 1 and Cohort A of part 2: Must have been treated with (a) anti-programmed death protein 1 (anti-PD-1) or programmed cell death ligand 1 (PD-L1) therapy and (b) platinum-based chemotherapy
- ✓ For Cohort B of Part 2: Previously treated with anti-PD-1/PD-L1 therapy for metastatic disease as the prior line of therapy
- ✓ For Cohort C of Part 2: Treatment naïve
- ✓ Adequate organ function
You may not qualify if…
- ✕ Active central nervous system (CNS) disease involvement
- ✕ Active autoimmune disease
- ✕ Active infection
- ✕ History of solid organ or hematologic stem cell transplantation
Where it's recruiting
Georgia
Newnan
New Jersey
Hackensack
New York
Buffalo · New York
Oregon
Portland
Pennsylvania
Philadelphia
Virginia
Fairfax
Source: ClinicalTrials.gov · NCT06116786 · last updated 2026-07-06